经肝动脉化疗栓塞术及其联合方案治疗肝细胞癌的现状与展望

胡泽鑫; 黄金涛; 仲斌演; 沈健; 朱晓黎

doi:10.12449/JCH240129

经肝动脉化疗栓塞术及其联合方案治疗肝细胞癌的现状与展望

DOI: 10.12449/JCH240129

苏州大学附属第一医院介入科，江苏苏州 215000

基金项目:

江苏省社会发展项目 (BE2021648)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：胡泽鑫负责收集整理文献，撰写论文；黄金涛、仲斌演、沈健负责修改论文；朱晓黎负责指导写作思路，指导撰写论文并最后定稿。

详细信息

通信作者:
朱晓黎， zhuxiaoli90@163.com （ORCID： 0000-0002-3507-2018）

计量
- 文章访问数: 173
- HTML全文浏览量: 80
- PDF下载量: 42
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-06
- 录用日期: 2023-05-17
- 出版日期: 2024-01-23

Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma

Department of Interventional Radiology，The First Affiliated Hospital of Soochow University，Suzhou，Jiangsu 215000，China

Research funding:

The Social Development Program of Jiangsu Province (BE2021648)

More Information

Corresponding author: ZHU Xiaoli， zhuxiaoli90@163.com （ORCID： 0000-0002-3507-2018）

摘要

摘要: 经肝动脉化疗栓塞术（TACE）是目前中晚期肝癌的主要治疗手段。本文从现有技术方式、人群选择、疗效评估等方面阐述了TACE在肝细胞癌中的应用现状，总结了TACE联合局部治疗、系统治疗的研究进展与前景，以期为相关临床实践及实验研究提供新的思路。
- 癌，肝细胞 /
- 化学栓塞，治疗性 /
- 肿瘤治疗方案
Abstract: Transarterial chemoembolization （TACE） is currently the primary treatment method for advanced liver cancer. This article elaborates on the current status of application of TACE in hepatocellular carcinoma from the aspects of existing techniques， patient selection， and efficacy assessment and summarizes the research advances and prospects of TACE combined with local treatment and systemic therapy， so as to provide new ideas for clinical practice and experimental studies.
- Carcinoma， Hepatocellular /
- Chemoembolization， Therapeutic /
- Antineoplastic Protocols

HTML全文

参考文献(53)

[1]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[2]	ZHENG RS, QU CF, ZHANG SW, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30( 6): 571- 579. DOI: 10.21147/j.issn.1000-9604.2018.06.01.
[3]	YAMADA R, SATO M, KAWABATA M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148( 2): 397- 401. DOI: 10.1148/radiology.148.2.6306721.
[4]	LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial[J]. Lancet, 2002, 359( 9319): 1734- 1739. DOI: 10.1016/S0140-6736(02)08649-X.
[5]	LO CM, NGAN H, TSO WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35( 5): 1164- 1171. DOI: 10.1053/jhep.2002.33156.
[6]	CHEN MJ, GUO XJ, SHEN L, et al. Monodisperse CaCO₃-loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment[J]. Int J Biol Macromol, 2023, 231: 123160. DOI: 10.1016/j.ijbiomac.2023.123160.
[7]	ZHU HD, LI X, JI JS, et al. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: A multicenter randomized phase II trial[J]. Eur Radiol, 2022, 32( 11): 7335- 7343. DOI: 10.1007/s00330-022-08848-7.
[8]	ZHANG W, ZHOU YJ, YAN ZP. Further discussion on the precision TACE therapy[J]. J Interv Radiol, 2021, 30( 10): 971- 975. DOI: 10.3969/j.issn.1008-794X.2021.10.001. 张雯, 周永杰, 颜志平. 再论精细TACE[J]. 介入放射学杂志, 2021, 30( 10): 971- 975. DOI: 10.3969/j.issn.1008-794X.2021.10.001.
[9]	MIYAYAMA S. Ultraselective conventional transarterial chemoembolization: When and how?[J]. Clin Mol Hepatol, 2019, 25( 4): 344- 353. DOI: 10.3350/cmh.2019.0016.
[10]	BZEIZI KI, ARABI M, JAMSHIDI N, et al. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: A systematic review and meta-analysis[J]. Cancers, 2021, 13( 24): 6172. DOI: 10.3390/cancers13246172.
[11]	LIU KL, JIN ZC, HU XL, et al. A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization[J]. Int J Biol Macromol, 2020, 142: 866- 878. DOI: 10.1016/j.ijbiomac.2019.10.026.
[12]	DURAN R, NAMUR J, PASCALE F, et al. Vandetanib-eluting radiopaque beads: Pharmacokinetics, safety, and efficacy in a rabbit model of liver cancer[J]. Radiology, 2019, 293( 3): 695- 703. DOI: 10.1148/radiol.2019190305.
[13]	IRIE T, KURAMOCHI M, TAKAHASHI N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: Measurement of balloon-occluded arterial stump pressure[J]. Cardiovasc Intervent Radiol, 2013, 36( 3): 706- 713. DOI: 10.1007/s00270-012-0476-z.
[14]	CHU HH, GWON DI, KIM GH, et al. Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: A propensity score matching analysis[J]. Eur Radiol, 2023, 33( 4): 2655- 2664. DOI: 10.1007/s00330-022-09284-3.
[15]	BUCALAU AM, TANCREDI I, PEZZULLO M, et al. Balloon-occluded chemoembolization for hepatocellular carcinoma: A prospective study of safety, feasibility and outcomes[J]. Hepat Oncol, 2020, 8( 1): HEP31. DOI: 10.2217/hep-2020-0022.
[16]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[17]	ZHONG BY, JIN ZC, CHEN JJ, et al. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma[J]. J Clin Transl Hepatol, 2023, 11( 2): 480- 489. DOI: 10.14218/JCTH.2022.00293.
[18]	PARK JW, CHEN M, COLOMBO M,, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35( 9): 2155- 2166. DOI: 10.1111/liv.12818.
[19]	KUDO M, UESHIMA K, CHAN S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh A liver function: A proof-of-concept study[J]. Cancers, 2019, 11( 8): 1084. DOI: 10.3390/cancers11081084.
[20]	WANG QH, XIA DD, BAI W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study[J]. J Hepatol, 2019, 70( 5): 893- 903. DOI: 10.1016/j.jhep.2019.01.013.
[21]	ZHANG S, WANG WS, ZHONG BY, et al. Subsequent treatment after transarterial chemoembolization failure/refractoriness: A review based on published evidence[J]. J Clin Transl Hepatol, 2022, 10( 4): 740- 747. DOI: 10.14218/JCTH.2021.00336.
[22]	KUDO M, MATSUI O, IZUMI N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update[J]. Oncology, 2014, 87( Suppl 1): 22- 31. DOI: 10.1159/000368142.
[23]	Clinical Guidelines Committee of Chinese College of Interventionalists. Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma[J]. J Intervent Radiol, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001. 中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31( 11): 1039- 1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.
[24]	JIN ZC, CHEN L, ZHONG BY, et al. Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study[J]. Transl Oncol, 2021, 14( 4): 101034. DOI: 10.1016/j.tranon.2021.101034.
[25]	MENG XP, WANG YC, JU SH, et al. Radiomics analysis on multiphase contrast-enhanced CT: A survival prediction tool in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. Front Oncol, 2020, 10: 1196. DOI: 10.3389/fonc.2020.01196.
[26]	LENCIONI R, BAERE TD, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64( 1): 106- 116. DOI: 10.1002/hep.28453.
[27]	SERGIO A, CRISTOFORI C, CARDIN R, et al. Transcatheter arterial chemoembolization(TACE) in hepatocellular carcinoma(HCC): The role of angiogenesis and invasiveness[J]. Am J Gastroenterol, 2008, 103( 4): 914- 921. DOI: 10.1111/j.1572-0241.2007.01712.x.
[28]	YANG Y, YU HL, QI LY, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2022, 39( 1): 455- 465. DOI: 10.1080/02656736.2022.2048095.
[29]	WANG L, KE Q, LIN NP, et al. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2019, 36( 1): 1288- 1296. DOI: 10.1080/02656736.2019.1692148.
[30]	SHETA E, EL-KALLA F, EL-GHARIB M, et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: A randomized-controlled study[J]. Eur J Gastroenterol Hepatol, 2016, 28( 10): 1198- 1203. DOI: 10.1097/MEG.0000000000000688.
[31]	SHIM SJ, SEONG J, HAN KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Liver Int, 2005, 25( 6): 1189- 1196. DOI: 10.1111/j.1478-3231.2005.01170.x.
[32]	HUO YR, ESLICK GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis[J]. JAMA Oncol, 2015, 1( 6): 756- 765. DOI: 10.1001/jamaoncol.2015.2189.
[33]	YOON SM, RYOO BY, LEE SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial[J]. JAMA Oncol, 2018, 4( 5): 661- 669. DOI: 10.1001/jamaoncol.2017.5847.
[34]	ZHU KS, CHEN JW, LAI LS, et al. Hepatocellular carcinoma with portal vein tumor thrombus: Treatment with transarterial chemoembolization combined with sorafenib: A retrospective controlled study[J]. Radiology, 2014, 272( 1): 284- 293. DOI: 10.1148/radiol.14131946.
[35]	CHUNG GE, LEE JH, KIM HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258( 2): 627- 634. DOI: 10.1148/radiol.10101058.
[36]	LYU N, KONG YN, MU LW, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69( 1): 60- 69. DOI: 10.1016/j.jhep.2018.02.008.
[37]	LIU BJ, GAO S, ZHU X, et al. Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: A propensity score-matched analysis[J]. Biomed Res Int, 2021, 2021: 6670367. DOI: 10.1155/2021/6670367.
[38]	HUANG JJ, HUANG WS, ZHAN MX, et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 1445- 1458. DOI: 10.2147/JHC.S339379.
[39]	ZHU ZX, WANG XX, YUAN KF, et al. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: A systematic review and meta-analysis[J]. HPB, 2018, 20( 9): 795- 802. DOI: 10.1016/j.hpb.2018.03.015.
[40]	LUO JJ, YAN ZP, LIU QX, et al. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein[J]. J Vasc Interv Radiol, 2011, 22( 4): 479- 489. DOI: 10.1016/j.jvir.2010.11.029.
[41]	WANG WS, WANG C, SHEN J, et al. Integrated I-125 seed implantation combined with transarterial chemoembolization for treatment of hepatocellular carcinoma with main portal vein tumor Thrombus[J]. Cardiovasc Intervent Radiol, 2021, 44( 10): 1570- 1578. DOI: 10.1007/s00270-021-02887-1.
[42]	LENCIONI R, LLOVET JM, HAN GH, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol, 2016, 64( 5): 1090- 1098. DOI: 10.1016/j.jhep.2016.01.012.
[43]	MEYER T, FOX R, MA YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma(TACE ‍2): A randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2( 8): 565- 575. DOI: 10.1016/S2468-1253(17)30156-5.
[44]	KUDO M, UESHIMA K, IKEDA M, et al. Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma[J]. Liver Cancer, 2022, 11( 4): 354- 367. DOI: 10.1159/000522547.
[45]	PENG ZW, FAN WZ, ZHU BW, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial(LAUNCH)[J]. J Clin Oncol, 2023, 41( 1): 117- 127. DOI: 10.1200/JCO.22.00392.
[46]	XIA DD, BAI W, WANG EX, et al. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study[J]. Liver Cancer, 2022, 11( 4): 368- 382. DOI: 10.1159/000523849.
[47]	SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 8): 525- 543. DOI: 10.1038/s41575-021-00438-0.
[48]	LLOVET JM, CASTET F, HEIKENWALDER M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19( 3): 151- 172. DOI: 10.1038/s41571-021-00573-2.
[49]	YANG C, ZHANG HL, ZHANG LM, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 4): 203- 222. DOI: 10.1038/s41575-022-00704-9.
[50]	CHENG AL, QIN SK, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
[51]	REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI₃05) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
[52]	ZHU HD, LI HL, HUANG MS, et al. Transarterial chemoembolization with PD-(L)₁ inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)[J]. Signal Transduct Target Ther, 2023, 8( 1): 58. DOI: 10.1038/s41392-022-01235-0.
[53]	HUANG JT, ZHONG BY, JIANG N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2022, 9: 1217- 1228. DOI: 10.2147/JHC.S386672.